Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions (TECNO)

February 5, 2026 updated by: Insel Gruppe AG, University Hospital Bern
TECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) proof-of-concept trial evaluating if additional administration of intra-arterial Tenecteplase (TNK) improves reperfusion in patients with incomplete mechanical thrombectomy (MT). For this purpose, 156 adult participants experiencing an acute ischemic stroke due to a large vessel occlusion with incomplete reperfusion with residual occlusions after MT will be randomly assigned to receive 3mg intra-arterial (IA) TNK or best medical treatment. Recruitment will occur at 20 academic tertiary stroke care centers in Switzerland, Spain, Belgium, and Germany and patients are followed up for 90 days after the index event. Showing superiority for reperfusion outcomes would have a major impact on the future management of stroke patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

156

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Graz, Austria, 8036
        • LKH-Universitätsklinikum Graz
      • Innsbruck, Austria, 6020
        • Medizinische Universität Innsbruck
      • Linz, Austria, 4020
        • Kepler Universitatsklinikum GmbH
      • Salzburg, Austria, 5020
        • Christian-Doppler-Klinik Salzburg
  • Belgium
      • Anderlecht, Belgium, 1070
        • Hôpital universitaires de Bruxelles
      • Bruges, Belgium, 8000
        • AZ Sint Jan Brugge AV
      • Brussels, Belgium, 1200
        • Cliniques Universitaires Saint-Luc
      • Brussels, Belgium, 1050
        • UZ Brussel
      • Ghent, Belgium, 9000
        • Universitair Ziekenhuis Gent
      • Leuven, Belgium, 3000
        • UZ Gasthuisberg Leuven
      • Liège, Belgium, 4000
        • Clinique CHC MontLégia
  • Finland
      • Helsinki, Finland, 00029
        • University Hospital Helsinki
  • Germany
      • Augsburg, Germany, 86156
        • Universitätsklinikum Augsburg
      • Bonn, Germany, 53127
        • Universitätsklinikum Bonn
      • Bremen, Germany, 28205
        • Klinikum Bremen-Mitte
      • Dresden, Germany, 01307
        • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
      • Erfurt, Germany, 99089
        • Helios Klinikum Erfurt
      • Frankfurt, Germany, 60528
        • Universitätsklinikum Frankfurt
      • Freiburg im Breisgau, Germany, 79106
        • Universitätsklinikum Freiburg
      • Göttingen, Germany, 37075
        • Universitatsmedizin Gottingen
      • Halle, Germany, 06120
        • Universitatsklinikum Halle (Saale)
      • Hamburg, Germany, 20246
        • Universitätsklinikum Hamburg-Eppendorf
      • Hamburg, Germany, 22763
        • Asklepios Klinik Altona
      • Kiel, Germany, 24105
        • Universitätsklinikum Schleswig-Holstein Campus Kiel
      • Magdeburg, Germany, 39120
        • Universitätsklinikum Magdeburg A. ö. R.
      • Mannheim, Germany, 68167
        • Universitätsmedizin Mannheim
      • Minden, Germany, 32429
        • Johannes Wesling Klinikum Minden
      • München, Germany, 81675
        • Klinikum rechts der Isar der Technischen Universität München
      • München, Germany, 81377
        • Klinikum der Universität München
      • Münster, Germany, 48149
        • Universitätsklinikum Münster
      • Solingen, Germany, 42653
        • Städtisches Klinikum Sollingen
      • Tübingen, Germany, 72076
        • Universitätsklinikum Tübingen
  • Netherlands
      • Amsterdam, Netherlands, 1100
        • Amsterdam UMC
      • Leiden, Netherlands, 2300
        • Leiden UMC
  • Portugal
      • Braga, Portugal, 4710-243
        • Hospital de Braga
      • Funchal, Portugal, 9000-177
        • Hospital Nelio Mendonca Funchal
      • Lisbon, Portugal, 1150-199
        • Lisbon Central University Hospital
      • Lisbon, Portugal, 1349-019
        • Hospital Eagas Moniz
      • Porto, Portugal, 4099-001
        • Hospital Santo Antonio
  • Switzerland
      • Aarau, Switzerland
        • Kantonsspital Aarau
      • Aarau, Switzerland, 5001
        • Kantonsspital Aarau
      • Aarau, Switzerland, 5001
        • Kantonsspital Aarau AG
      • Basel, Switzerland
        • Universitätsspital Basel
      • Bern, Switzerland, 3010
        • Universitätsspital Bern
      • Geneva, Switzerland, 1211
        • Hopitaux universitaires de Geneve
      • Lausanne, Switzerland, 1011
        • Centre Hospitalier Universitaire Vaudois
      • Lausanne, Switzerland, 1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
      • Lausanne, Switzerland
        • University Hospital of Lausanne
      • Lucerne, Switzerland, 6000
        • Kantonsspital Luzern
      • Lugano, Switzerland, 6900
        • Ospedale Regionale di Lugano
      • Sankt Gallen, Switzerland, 9007
        • Kantonsspital St.Gallen
      • Zurich, Switzerland, 8091
        • Universitatsspital Zurich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Informed consent
  • Age ≥18 years
  • Clinical signs consistent with an acute ischemic stroke
  • Patient had an initial vessel occlusion in the anterior or posterior circulation defined as intracranial ICA, M1, M2, M3, A1, A2, P1 or P2
  • Patient has undergone endovascular stroke treatment
  • Onset to randomization no later than < 705 minutes (11h 45min) after symptom-onset/last-seen well.

  • Incomplete reperfusion defined as any of the following:

    1. For ICA/M1: TICI2b/2c (50-99%) reperfusion after endovascular treatment without mechanically amendable target-occlusion (as per definition by the interventionalist).
    2. For A1/A2, P1/P2, M2/M3: TICI2a/2b/2c (1-99%) reperfusion after endovascular treatment without mechanically amendable target-occlusion (as per definition by the interventionalist).
    3. Any emboli to new territory without mechanically amendable target-occlusion (as per definition by the interventionalist).
  • Signs of early ischemic changes of non-contrast CT Alberta Stroke Program Early CT Score (ASPECTS) ≥5 (for DWI-ASPECTS ≥ 4, for DWI-ASECTS: a region must have diffusion abnormality in 20% or more of its volume to be considered DWI-ASPECTS positive)

Exclusion Criteria

  • Acute intracranial hemorrhage
  • Contraindication to MRI (e.g. pacemaker)
  • Any severe bleeding within the past 6 months, which would prevent administration of intravenous thrombolysis in clinical routine Major surgery in the past 2 months with severe risk of bleeding, which would prevent administration of intravenous thrombolysis in clinical routine
  • Intake of Vitamin K antagonists with INR >1.7
  • Platelets < 50,000
  • Non-controlled hypertension (defined as SBP >185 mmHg or DBP >110 mmHg refractory to treatment)
  • Active dyspeptic ulcer
  • Known arterial aneurysm
  • Known neoplasms with risk of bleeding
  • Severe liver fibrosis or portal hypertension
  • Acute pericarditis
  • Acute endocarditis
  • Acute pancreatitis
  • Known allergy to TNK or Gentamicin or other additives/auxiliaries (Polysorbatum 20, L-Argininum, Acidum phosphoricum)
  • Known Renal failure either as defined by a serum creatinine > 3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate [GFR] < 30 or as subject who required hemodialysis/peritoneal dialysis
  • Radiological confirmed evidence of mass effect or intracranial tumor (except small meningioma)
  • Radiological confirmed evidence of cerebral vasculitis
  • Calcified thrombi
  • Pregnancy or lactating women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Best Medical Treatment (standard of care)
Patients will receive standard of care as per current ESO guidelines.
Experimental: Intra-arterial Tenecteplase
Patients will receive intra-arterial administration of Tenecteplase using a standard approved microcatheter.
Drug: Tenecteplase
Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Early reperfusion of the residual intracranial occlusion(s)
Time Frame: 25 minutes after randomization
Defined by reperfusion improvement on angiography images
25 minutes after randomization
Late reperfusion of the residual intracranial occlusion(s)
Time Frame: 24 hours ±6 hours
Defined by complete reperfusion on perfusion imaging
24 hours ±6 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Degree of disability or dependence assessed by the modified ranking scale (mRS) (shift analysis)
Time Frame: 90 days+/-15 days
mRS
90 days+/-15 days
Normalized change in National Institute of Health Score Scale (NIHSS)
Time Frame: 24 hours +/- 6 hours post-randomization
NIHSS
24 hours +/- 6 hours post-randomization
Change in National Institute of Health Score Scale (NIHSS)
Time Frame: 90 days +/- 15 days post-randomization
NIHSS
90 days +/- 15 days post-randomization
Quality of life as assessed by the EuroQol 5D-3L (EQ-5D-3L)
Time Frame: 90 days +/- 15 days
EuroQol 5D-3L
90 days +/- 15 days
All-cause mortality
Time Frame: 90 days
Mortality
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Insel Gruppe AG, University Hospital Bern

Investigators

  • Study Director: Urs Fischer, PhD, NCTU

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 21, 2023

Primary Completion (Actual)

October 9, 2025

Study Completion (Actual)

October 9, 2025

Study Registration Dates

First Submitted

April 26, 2022

First Submitted That Met QC Criteria

August 11, 2022

First Posted (Actual)

August 12, 2022

Study Record Updates

Last Update Posted (Actual)

February 10, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-00388

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ischemic Stroke

Clinical Trials on Tenecteplase

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe